AIP
TSHA icon

Ameritas Investment Partners’s Taysha Gene Therapies TSHA Stock Holding History

Ameritas Investment Partners’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$79K Hold
17,672
– – ﹤0.01% 1830
2025
Q4 		$97.2K Buy
17,672
+2,000
+13% +$9.71K ﹤0.01% 1717
2025
Q3 		$51.2K Hold
15,672
– – ﹤0.01% 2101
2025
Q2 		$36.2K Hold
15,672
– – ﹤0.01% 2376
2025
Q1 		$21.8K Hold
15,672
– – ﹤0.01% 2517
2024
Q4 		$27.1K Hold
15,672
– – ﹤0.01% 2501
2024
Q3 		$31.5K Hold
15,672
– – ﹤0.01% 2432
2024
Q2 		$35.1K Buy
+15,672
New +$45.6K ﹤0.01% 2333
2022
Q2 		– Sell
-1,745
Closed -$11K – 3235
2022
Q1 		$11K Hold
1,745
– – ﹤0.01% 2771
2021
Q4 		$20K Hold
1,745
– – ﹤0.01% 2656
2021
Q3 		$32K Hold
1,745
– – ﹤0.01% 2440
2021
Q2 		$37K Buy
1,745
+1,018
+140% +$23.5K ﹤0.01% 2390
2021
Q1 		$15K Hold
727
– – ﹤0.01% 2692
2020
Q4 		$19K Buy
+727
New +$15.7K ﹤0.01% 2504

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ameritas Investment Partners's TSHA Position: Q1 2026 in Review

Ameritas Investment Partners held its Taysha Gene Therapies (TSHA) position steady in Q1 2026 at 17,672 shares worth $79K. The position accounts for ﹤0.01% of the portfolio, ranked #1830.

Ameritas Investment Partners first reported a position in TSHA in Q4 2020 and has held it in 14 quarters since. The position peaked at $97.2K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Ameritas Investment Partners held 17,672 shares of Taysha Gene Therapies worth $79K as of Q1 2026.
  • Ameritas Investment Partners left its Taysha Gene Therapies share count unchanged in Q1 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #1830 holding.
  • Ameritas Investment Partners first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 14 quarters since.
  • Ameritas Investment Partners's Taysha Gene Therapies position peaked at $97.2K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.